Cardiac fatty acid binding protein as a biomarker for long-term prognosis of clinically manifested heart failure and severe post-infarction left ventricular myocardial remodeling

The aim of the study is to evaluate cardiac fatty acid binding protein as a prognostic biomarker for the occurrence of severe post-infarction structural and functional remodeling of the left ventricular myocardium and heart failure with clinical manifestations in patients with acute myocardial infarction during long-term follow-up. Material and methods. The study included 95 patients with acute myocardial infarction and ST-segment elevation (mean age 56.8 ± 9.8 years). Upon admission to the emergency room, all patients underwent clinical and laboratory studies to determine cardiac fatty acid binding protein (cFABP) and high-sensitivity troponin T (hs-TnT). At the end of the long-term follow-up (Me = 36 months), the patients were examined for clinically evident heart failure (NYHA functional class II and higher), high-sensitivity C-reactive protein (hsCRP) was determined in the blood, and echocardiography was performed. According to the echocardiography data, the presence and severity of structural and functional remodeling of the left ventricle myocardium (SFR LV) were established. Results. It was determined that the presence of clinically evident heart failure is directly associated with age, the Charlton comorbidity index, cFABP ≥10 ng/ml upon admission to the hospital and has a direct tendency to be associated with hs-TnT upon admission to the hospital. The presence of severe structural and functional remodeling of the left ventricle myocardium is directly associated with age, obesity, creatinine, cFABP ≥ 10 ng/ml and hs-TnT upon admission to hospital, and there is also a direct tendency towards an association with age. It was revealed that hs-TnT upon admission to hospital is directly associated with hsCRP ≥ 2 mg/l at the end of long-term followup. Conclusions. the presence of cFABP ≥ 10 ng/ml in the blood of patients with acute myocardial infarction upon admission to hospital is associated with an increase in the probability of developing clinically evident heart failure during long-term follow-up by 4.27 times, and severe structural and functional remodeling of the left ventricle myocardium is 3.07 times more likely, which is due to the size of the infarction lesion and the subsequent development of myocardial fibrosis.

1. Кожевникова М.В., Беленков Ю.Н. Биомаркеры сердечной недостаточности: настоящее и будущее. Кардиология, 2021; 61 (5): 4–16. doi: 10.18087/cardio.2021.5.n1530 [Kozhevnikova M.V., Belenkov Yu.N. Biomarkers in heart failure: current and future. Cardiology, 2021; 61 (5): 4–16. (In Russ.)]. doi: 10.18087/cardio.2021.5.n1530

2. Ullah A., Sajid S., Qureshi M., Kamran M., Anwaar M.A., Naseem M.A., Zaman M.U., Mahmood F., Rehman A., Shehryar A., Nadeem M.A. Novel biomarkers and the multiple-marker approach in early detection, prognosis, and risk stratification of cardiac diseases: A narrative review. Cureus, 2023; 15 (7): e42081. doi: 10.7759/cureus.42081

3. Алиева А.М., Байкова И.Е., Резник Е.В., Пинчук Т.В., Шнахова Л.М., Валиев Р.К., Сарыев М.Н., Рахаев А.М., Ковтюх И.В., Никитин И.Г. Сердечный белок, связывающий жирные кислоты, – перспективный биологический маркер при сердечной недостаточности. РМЖ. Медицинское обозрение, 2022; 6 (1): 5–11. doi: 10.32364/2587-6821-2022-6-1-5-11 [Alieva A.M., Baykova I.E., Reznik E.V., Pinchuk T.V., Shnakhova L.M., Valiev R.K., Saryev M.N., Rakhaev A.M., Kovtyukh I.V., Nikitin I.G. Heart-type fatty acid binding protein: the promising biological marker in heart failure. Russian Medical Inquiry, 2022; 6 (1): 5–11. (In Russ.)]. doi: 10.32364/2587-6821-2022-6-1-5-11

4. Byrne R.A., Rossello X., Coughlan J.J., Barbato Е., Berry C., Chieffo A., Claeys M.J., Dan G.A., Dweck M.R., Galbraith M., Gilard M., Hinterbuchner L., Jankowska E.A., Jüni P., Kimura T., Kunadian V., Leosdottir M., Lorusso R., Pedretti R.F.E., Rigopoulos A.G., Rubini Gimenez M., Thiele H., Vranckx P., Wassmann S., Wenger N.K., Ibanez B.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur. Heart. J., 2023; 44 (38): 3720–3826. doi: 10.1093/eurheartj/ehad191

5. Galli A., Lombardi F. Postinfarct left ventricular remodelling: A prevailing cause of heart failure. Cardiol. Res. Pract., 2016: 2579832. doi: 10.1155/2016/2579832

6. Flachskampf F.A., Schmid M., Rost С., Achenbach S., Demaria A.N., Daniel W.G. Cardiac imaging after myocardial infarction. Eur. Heart. J., 2011; 32 (3): 272–283. doi: 10.1093/eurheartj/ehq446

7. Schneider M.P., Schmid M., Nadal J., Wanner C., Krane V., Floege J., Saritas T., Busch M., Sitter T., Friedrich N., Stockmann H., Meiselbach H., Nauck M., Kronenberg F., Eckardt K.U.; GCKD Study Investigators. Heart-type fatty acid binding protein, cardiovascular outcomes, and death: Findings from the German CKD Cohort Study. Am. J. Kidney Dis., 2022; 80 (4): 483–494.e1. doi: 10.1053/j.ajkd.2022.01.424

8. Wu Y.W., Ho S.K., Tseng W.K., Yeh H.I., Leu H.B., Yin W.H., Lin T.H., Chang K.C., Wang J.H., Wu C.C., Chen J.W. Potential impacts of high-sensitivity creatine kinase-MB on long-term clinical outcomes in patients with stable coronary heart disease. Sci. Rep., 2020; 10 (1): 5638. doi: 10.1038/s41598020-61894-3

9. Wang S., Liu K., Guan S., Cui G. Prognostic value of prealbumin, N-terminal pro-B-type natriuretic peptide, heart type fatty acid binding protein, and cardiac troponin I in elderly patients for heart failure and poor outcomes. J. Int. Med. Res., 2021; 49 (5): 300060521999742. doi: 10.1177/0300060521999742

10. Mazhar F., Faucon A.L., Fu E.L., Szummer K.E., Mathisen J., Gerward S., Reuter S.B., Marx N., Mehran R., Carrero J.J. Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease. Eur. Heart. J., 2024: ehae557. doi: 10.1093/eurheartj/ehae557

11. Ahmad F., Karim A., Khan J., Qaisar R. Circulating HFABP as a biomarker of frailty in patients with chronic heart failure. Exp. Biol. Med. (Maywood), 2023; 248 (16): 1383–1392. doi: 10.1177/15353702231198080

12. Никитин Ю.П., Панин Л.Е., Воевода М.И., Симонова Г.И., Душкин М.И., Рагино Ю.И., Николаев К.Ю., Рябиков А.Н., Денисова Д.В., Тихонов А.В., Шварц Я.Ш. Вопросы атерогенеза. Новосибирск: Ротапринт СНИИГГиМСа, 2005. С. 372. [Nikitin Yu.P., Panin L.E., Voevoda M.I., Simonova G.I., Dushkin M.I., Ragino Yu.I., Nikolaev K.Yu., Ryabikov A.N., Denisova D.V., Tikhonov A.V., Shvarts Ya.Sh. Issues of atherogenesis. Novosibirsk: Rotaprint SNIIGGiMS, 2005. P. 372 (In Russ.)].

13. Taqueti V.R., Shah A.M., Everett B.M., Pradhan A.D., Piazza G., Bibbo C., Hainer J., Morgan V., Carolina do A H de Souza A., Skali H., Blankstein R, Dorbala S., Goldhaber S.Z., Le May M.R., Chow B.J.W., deKemp R.A., Hage F.G., Beanlands R.S., Libby P., Glynn R.J., Solomon S.D., Ridker P.M., Di Carli M.F. Coronary flow reserve, inflammation, and myocardial strain: The CIRT-CFR Trial. JACC Basic Transl. Sci., 2022; 8 (2): 141–151. doi: 10.1016/j.jacbts.2022.08.009

14. Anstensrud A.K., Woxholt S., Sharma K., Broch K., Bendz B., Aakhus S., Ueland T., Amundsen B.H., Damås J.K., Hopp E., Kleveland O., Stensæth K.H., Opdahl A., Kløw N.E., Seljeflot I., Andersen G.Ø., Wiseth R., Aukrust P., Gullestad L. Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI). Open Heart, 2019; 6 (2): e001108. doi: 10.1136/openhrt-2019-001108

15. Deng Y., Pang X., Chen L., Peng W., Huang X., Huang P., Zhao S., Li Z., Cai X., Huang Q., Zeng J., Feng Y., Chen B. IFI-16 inhibition attenuates myocardial remodeling following myocardial infarction. iScience, 2024; 27 (8): 110568. doi: 10.1016/j.isci.2024.110568